The France cell therapy market is set to record a CAGR of 15.92% during the forecast period, 2022-2028, and is projected to garner a revenue of $283.71 million by 2028.

The France cell therapy market growth prospects are accredited to the presence of more than ten globally-leading research and biotech groups working in cell and gene therapies. Also, the government is encouraging gene therapy developments by facilitating the acceptance of clinical trials and enabling the integration of small gene therapy research centers and hospitals that further encourage industrial partners to invest in gene therapy programs.

To know more about this report, request a free sample copy

Furthermore, the European Medicines Agency (EMA) approved two European Novartis sites in Switzerland and France in August 2020 for the commercial manufacturing of chimeric antigen receptor T-cell cell therapies. Additionally, in September 2021, Biotech TreeFrog Therapeutics, a French biotech startup, secured $75 million in investments to accelerate the development of its biomimetic C-Stem technology. Besides, the government allocated 7 million euros in February 2022 to the OPTI-STEM project that entails employing the systems biology methodology for the production of MSCs for therapeutic purposes. Such initiatives and developments boost the France cell therapy market growth.

The France cell therapy market segmentation includes end-user, therapy type, cell type, and therapeutic application. The therapeutic application segment includes malignancies, autoimmune disorders, musculoskeletal disorders, dermatology, and other applications.

Cartistem, Invossa, Carticel, and MACI are among the approved cellular therapies for treating musculoskeletal conditions, including knee cartilage and osteoarthritis. However, the use of cell-based therapies for illnesses and injuries affecting skeletal muscle, bones, joints, and tendons are still being investigated. In addition, the regenerative treatment approach is expected to aid in the management of patients suffering from musculoskeletal conditions.

Further, with regard to the treatment of skin and hair-related conditions, GINTUIT, LAVIV (Azficel-T), TrichoCyte (ICX-TRC), and Epicel are the approved cell therapies. Also, physicians are evaluating the use of stem cell therapy for genetic diseases like recessive dystrophic epidermolysis bullosa. Accordingly, fibroblasts and keratinocytes from human skin are studied for their regenerative capacity. These facilitate the development of cell-based therapies for treating patients with skin disorders. Besides, bioengineered skin products and cultured cells are being sold for treating patients with inherited and acquired skin disorders associated with defective skin.

In the case of autoimmune diseases, cell therapy tests have been successful. Autologous Hematopoietic Stem Cell Transplantation (HSCT) is considered a feasible solution for conditions with poor prognoses like lupus, scleroderma, and multiple sclerosis. Moreover, several cancer types treated by stem cell transplantation include germ-cell tumors, ovarian cancer, acute myeloid leukemia, non-Hodgkin lymphoma, etc.

Besides, cell therapies have been shown to have significant potential in cancer treatment. Also, these can be deployed as novel delivery platforms to target both metastatic and primary tumor foci. This is attributed to the unique characteristics of stem cells like immunosuppression, migration toward cancer cells, and secretion of bioactive factors. Such characteristics help address challenges in cancer management.

Some of the leading companies in the France cell therapy market are TheraVectys, Sangamo Therapeutics Inc, Cellectis, Bristol Myers Squibb Company, etc.

Cellectis is a biopharmaceutical company that produces genome-edited chimeric antigen receptor T-cell therapies for cancer immunotherapy. It uses its gene-editing platform for developing life-saving cell and gene therapies. The company has its headquarters in Paris, France.

The company develops product candidates based on UCAR T-cells, also called universal chimeric antigen receptors that target cancer cells.

Report Synopsis

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.